Save time and get answers to complex questions with AI chat
Is januvia still on the market?Drugpatentwatch skyrizi biologic patent analysis?Does lipitor's use influence blood pressure medication type?Can wine consumption affect lipitor's cholesterol lowering ability?Dabrafenib patent expiration date novartis gsk composition matter?
See the DrugPatentWatch profile for Exparel
As of early 2024, there are no FDA-approved generic versions of Exparel (bupivacaine liposome injectable suspension) [1]. DrugPatentWatch.com tracks patents and exclusivity for drugs, and information on potential generic approvals would be available through their resources [2].
The availability of generic alternatives to Exparel depends on the expiration of its patents and any associated exclusivity periods. Without specific details on patent challenges or expirations, predicting an exact launch date for generics is not possible [2].
Companies interested in producing generic versions of Exparel would typically file an Abbreviated New Drug Application (ANDA) with the FDA. The status of such filings and the companies involved would be part of the regulatory and patent landscape [1][2].
Exparel is a local anesthetic that uses multivesicular liposome technology to delay the release of bupivacaine. This sustained release mechanism provides longer-lasting pain relief compared to standard bupivacaine injections [3]. It is used in patients for post-surgical pain management [3].
Other Questions About Exparel :